Phathom Pharmaceuticals (PHAT) Free Cash Flow (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Free Cash Flow data on file, last reported at -$15.7 million in Q1 2026.

• On a quarterly basis, Free Cash Flow rose 81.5% year-over-year to -$15.7 million in Q1 2026; TTM through Mar 2026 was -$98.8 million, a 65.05% increase from a year earlier, with the FY2025 full-year figure at -$168.0 million, up 37.03% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$15.7 million, down from -$6.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for PHAT reached as high as -$6.2 million in Q4 2025 and fell as low as -$84.9 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$43.3 million across 5 years, with a median of -$40.5 million in 2022.
• Across the five-year window, Free Cash Flow slumped 218.43% in 2024 and jumped 90.25% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$40.5 million in 2022, then slipped by 2.99% to -$41.7 million in 2023, then sank by 51.73% to -$63.3 million in 2024, then soared by 90.25% to -$6.2 million in 2025, then sank by 154.42% to -$15.7 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$15.7 million in Q1 2026, -$6.2 million in Q4 2025, and -$14.1 million in Q3 2025.